POOR RECRUITMENT

The aim of the clinical trial is to evaluate the EndoRotor®'s ability to completely remove areas of Barrett's esophagus considered refractory after 3 failed ablation treatments (Radiofrequency Ablation (RFA) and/or Cryotherapy) or in patients with at least 1 failed ablative procedure (RFA and/or Cryotherapy) and are intolerant to the procedure due to pain, where intolerant is defined as post-dysphagia or odynophagia persisting for 24 hours or greater or requiring narcotic analgesia for a duration of more than 24 hours.

Prospective, multi-center, randomized controlled trial, pivotal, investigational device exemption (IDE) to compare the safety and performance of the EndoRotor® Mucosal Resection System with continued ablative therapy in subjects with refractory Barrett's Esophagus.

The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.

Inclusion Criteria:

1. Subjects who are greater than 30 and less than 90 years of age; inclusive of males and females.

2. Subjects with confirmed Barrett's esophagus with dysplasia (low-grade or high-grade) and meeting at least one of the following criteria:

   1. Failed 3 ablative procedures (RFA and/or Cryotherapy).
   2. Failed at least 1 ablative procedure (RFA and/or Cryotherapy) and are intolerant to the procedure due to pain, where intolerant is defined as post-procedure dysphagia or odynophagia persisting for 24 hours or greater or requiring narcotic analgesia for a duration of more than 24 hours.

3. Residual Barrett's length is ≥1 cm and ≤6 cm.

4. No confirmed evidence of esophageal adenocarcinoma (EAC) at the time of therapy.

5. Subject capable of giving informed consent.

6. Subject has a reasonable expectation for prolonged survival (greater than 2 years).

7. Subject can tolerate repeated endoscopic procedures.

8. Absence of strictures refractory to dilation that preclude the passage of the endoscope

9. Patients who were on acid suppression therapy (i.e. PPIs) during the course of failed primary ablative therapy, and who can continue acid suppression therapy for the entire time they are on the clinical study.

10. Subjects with the ability to understand the requirements of the study, who have provided written informed consent, and who are willing and able to return for the required follow-up assessments through 12 months, as indicated.

Exclusion Criteria:

1. Subject unable to give informed consent.
2. Subject is unwilling to return for repeated endoscopies.
3. Confirmed endoscopic and or histologic evidence of EAC at time of therapy.
4. Residual Barrett's longer than 6 cm.
5. Subjects with nodular Barrett's esophagus.
6. Subjects who are on anticoagulant therapy that cannot be discontinued for 5 days before and after the procedure.
7. Subjects with known coagulopathy defined as abnormal prothrombin or partial thromboplastin time.
8. History of esophageal varices
9. LA Grade B, C, or D esophagitis.
10. Esophageal stricture refractory to dilation preventing passage of endoscope or catheter.
11. Any previous esophageal surgery, except fundoplication without complications.
12. Medically uncorrectable hypotension or hypertension.
13. Any condition that in the opinion of the investigator would create an unsafe clinical situation that would not allow the patient to safely undergo an endoscopic procedure (lack of medical clearance).
14. Pregnant or lactating women or women of childbearing potential who do not employ a reliable method of contraception as judged by the Investigator, and/or are not willing to use reliable contraception for the duration of study participation.
15. Subject has known severe psychiatric disorder, substance abuse, or other reason for being unable to follow trial follow-up instructions.
16. Patient has a known significant concomitant illness with a life expectancy of less than 2 years.
17. Subject is known to be currently enrolled in another investigational trial that could interfere with the endpoint analyses of this trial.